Promoter polymorphism of the gene for CD14 receptor is not associated with sub-clinical carotid atherosclerosis in a community population

European Journal of Preventive Cardiology

Volumn 11, Issue 4, 2004, Pages 344-349

  Hung, Joseph ^a,b   Mcquillan, Brendan M ^a,b   Chapman, Caroline M l ^c   Thompson, Peter L ^a,b   Beilby, John P ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c Western Australian Centre for Pathology and Medical Research   (Australia)

Author keywords

atherosclerosis; carotid ultrasound; CD14; Chlamydia pneumoniae; gene polymorphism; intima medial wall thickness; smoking

Indexed keywords

CD14 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADULT; AGED; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; IMMUNOFLUORESCENCE TEST; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

ADULT; AGED; ANTIGENS, CD14; AUSTRALIA; CAROTID ARTERY DISEASES; CAROTID ARTERY, COMMON; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK FACTORS; TUNICA INTIMA;

EID: 4344631283     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000129741.07723.6c     Document Type: Article

References (32)

1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–126.
2. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431–1433.
3. Schumann RR, Rietschel ET, Loppnow H. The role of CD14 and lipopolysaccharide binding protein (LBP) in the activation of different cell types by endotoxin. Med Microbiol Immunol 1994; 183: 279–297.
4. Zhang DE, Hetherington CJ, Tan S, Dziennis SE, Gonzales DA, Chen HM, et al. Sp 1 is a critical factor for the monocyte specific expression of human CD14. J Biol Chem 1994; 269: 11425–11434.
5. Baldini M, Lohman IC, Halonen M, Eriksen RP, Holt PG, Martinez FD. A polymorphism in the 5ℙ flanking region of the CD14 gene is associated with circulating CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20: 976–983.
6. Unkelbach K, Gardemann A, Kostrzewa M, Philipp M, Tillmanns H, Haberbosch W. A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol 1999; 19: 932–938.
7. Koenig W, Khuseyinova N, Hoffmann MM, Marz W, Frohlich M, Hoffmeister A, et al. CD14C(−260) $ T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease. J Am Coll Cardiol 2002; 40: 34–42.
8. Hubacek JA, Rothe G, Pit'ha J, Skodova Z, Stanek V, Poledne R, et al. C(−260)T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999; 99: 3218–20.
9. Kane JP, Havel RJ. Polymorphism of the lipopolysaccharade receptor (CD14) and myocardial infarction. New evidence for a role of gram-negative bacterial infection? Circulation 1999; 99: 3210–3212.
10. Shimada K, Watanabe Y, Mokuno H, Iwama Y, Daida H, Yamaguchi H. Common polymorphism in the promoter of the CD14 monocyte receptor gene is associated with acute myocardial infarction in Japanese men. Am J Cardiol 2000; 86: 682–684.
11. Zee RY, Lindpaintner K, Struk B, Hennekens CH, Ridker PM. A prospective evaluation of the CD14C(−260)T gene polymorphism and the risk of myocardial infarction. Atherosclerosis 2001; 154: 699–702.
12. Koch W, Kastrati A, Mehilli J, von Beckerath N, Schomig A. CD14 gene −159C/T polymorphism is not associated with coronary artery disease and myocardial infarction. Am Heart J 2002; 143: 971–976.
13. McQuillan BM, Beilby JP, Nidorf M, Thompson PL, Hung J. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Circulation 1999; 99: 2383–2388.
14. Hung J, McQuillan BM, Nidorf M, Thompson PL, Beilby JP. Angiotensinconverting enzyme gene polymorphism and carotid wall thickening in a community population. Arterioscler Thromb Vasc Biol 1999; 19: 1969–1974.
15. Hasday JD, Bascom R, Costa J, Fitzgerald T, Dubin W. Bacterial endotoxin is an active component of cigarette smoke. Chest 1999; 115: 829–835.
16. Risk Factor Prevalence Study Management Committee. Risk factor prevalence study: survey no 3 1989. Canberra: National Heart Foundation of Australia and Australian Institute of Health; 1990; 141.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
18. Coles KA, Plant AJ, Riley TV, Smith DW, McQuillan BM, Thompson PL. Lack of association between seropositivity to Chlamydia pneumoniae and carotid atherosclerosis. Am J Cardiol 1999; 84: 825–828.
19. Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific Publications, 1994.
20. McCullagh P, Nelder J. Generalized linear models. London: Chapman and Hall, 1989.
21. Zee RY, Bates D, Ridker PM. A prospective evaluation of the CD14 and CD18 gene polymorphisms and risk of stroke. Stroke 2002; 33: 892–895.
22. Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994; 236: 567–573.
23. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432–1437.
24. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older patients. N Engl J Med 1999; 340: 14–22.
25. Risley PB, Jerrard-Dunne PM, Sitzer MMD, Buehler AMD, von Kegler SMD, Markus HSF. Promoter polymorphism in the endotoxin receptor (CD14) is associated with increased carotid atherosclerosis only in smokers: the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2003; 34: 600–604.
26. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schrazberger P, Egger G, Oberhollenzer F, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease. J Am Coll Cardiol 1999; 34: 1975–1981.
27. Wurfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Experimental Med 1995; 181: 1743–1754.
28. Haziot A, Rong GW, Bazil V, Silver J, Goyert SM. Recombinant soluble CD14 inhibits LPS-induced tumour necrosis factor-alpha production by cells in whole blood. J Immunol 1995; 154: 6529–6532.
29. Vita JA, Loscalzo J. Shouldering the risk factor burden. Infection, atherosclerosis, and the vascular endothelium. Circulation 2002; 106: 164–166.
30. Saikku P. Chlamydia pneumoniae in atherosclerosis. J Intern Med 2000; 247: 391–396.
31. Markus HS, Sitzer M, Carrington D, Mendall MA, Steinmetz H. Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis. Circulation 1999; 100: 832–837.
32. Espinola-Klein CMD, Rupprecht H-JMD, Blankenberg SMD, Bickel CMD, Kopp HMD, Rippin GP, et al. Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, Cytomegalovirus, or Herpes simplex virus infection? Stroke 2000; 31: 2127–2133.